Cartilage Degeneration Market Report 2025

This Cartilage Degeneration market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The cartilage degeneration market size has grown strongly in recent years. It will grow from $12.63 billion in 2024 to $13.4 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to aging population, joint injuries, obesity epidemic, sports injuries, limited self-repair capacity.

The cartilage degeneration market size is expected to see strong growth in the next few years. It will grow to $16.62 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to regenerative medicine advancements, biologic injections, tissue engineering solutions, precision medicine, robotics-assisted surgery. Major trends in the forecast period include stem cell therapies, 3D printing in orthopedics, gene therapy for cartilage repair, personalized rehabilitation programs, telemedicine for follow-up care.

The rising prevalence of obesity is expected to drive the growth of the cartilage degeneration market in the coming years. Obesity, a condition characterized by excessive body fat accumulation, poses significant health risks. It contributes to cartilage degeneration by increasing compressive forces on cartilage and promoting inflammatory cytokines. This condition leads to several pathological changes in the knee joint, such as abnormal joint loading, misalignment, and muscle weakness. For example, data from the Government Digital Service in the UK revealed that in 2021-2022, 63.8% of adults aged 18 and older were classified as overweight or obese, up from 63.3% the previous year. Additionally, the obesity rate among adults increased from 25.2% in 2020-2021 to 25.9%. These statistics highlight the growing impact of obesity, which is fueling the expansion of the cartilage degeneration market.

The growth of the cartilage degeneration market is also being propelled by the increasing elderly population. Individuals aged 65 and older experience muscle and bone mass loss, leading to reduced strength and joint functionality. Cartilage degeneration treatments play a vital role in mitigating age-related changes in the musculoskeletal system, strengthening bones, and slowing bone loss. According to the World Health Organization (WHO), the global population aged 60 and older is projected to rise from 1 billion in 2020 to 1.4 billion by 2030, and 2.1 billion by 2050. Furthermore, the population aged 80 and older is expected to triple from 143 million in 2020 to 426 million by 2050. This demographic trend is a key driver of the cartilage degeneration market.

Leading companies in the cartilage degeneration market are innovating products to enhance cartilage repair and regeneration. One such product is Agili-C, a cell-free implant used to treat cartilage and osteochondral defects in traumatic and osteoarthritic joints. In July 2023, CartiHeal Ltd., an Israeli medical device company, announced the first commercial implantation of Agili-C. Made from natural calcium carbonate derived from coral exoskeletons, the implant stimulates chondrocyte migration and extracellular matrix deposition. This design promotes natural cartilage and bone regeneration without relying on cells or growth factors. The implant’s approval reinforces its safety and efficacy, benefiting patients and healthcare providers.

Companies in the cartilage degeneration market are increasingly focusing on regenerative therapies to strengthen their market positions. These therapies leverage advanced biological methods to restore damaged cartilage, promoting natural healing. For instance, in 2023, Zimmer Biomet, a U.S.-based medical device company, introduced its Tissue Regeneration System. This system employs proprietary scaffold technology made of biocompatible materials to support cartilage repair. It also offers customizable options to meet individual patient needs, improving healing outcomes and recovery times. Such innovations highlight a shift toward personalized medicine, addressing osteoarthritis and sports injuries while enhancing patient satisfaction.

In July 2022, Bioventus Inc., a U.S.-based company specializing in active healing and surgical orthobiologics, acquired CartiHeal for $315 million. This acquisition aims to bolster Bioventus' joint preservation technologies, contributing to its growth strategy and supporting its goal of sustained double-digit revenue growth. CartiHeal Ltd. develops proprietary implants for treating cartilage and osteochondral defects in traumatic and osteoarthritic joints, further enriching Bioventus' portfolio.

Cartilage degeneration refers to the progressive deterioration or breakdown of cartilage, a smooth and flexible connective tissue that covers the ends of bones in joints. This tissue acts as a cushion, enabling smooth joint movement by minimizing friction between bones. The degeneration of cartilage can result in pain, stiffness, and reduced joint functionality.

Common procedures to address cartilage degeneration include joint replacements, chondroplasty, osteochondral transplants, microfracture, meniscus transplants, cell-based cartilage resurfacing, and autologous chondrocyte implantation. Joint replacements involve surgically replacing a damaged or diseased joint with an artificial prosthesis. These procedures are applied to various joints such as the knee and hip and are performed in settings like hospitals, specialty clinics, ambulatory surgical centers, and academic or research institutes.

The cartilage degeneration market research report is one of a series of new reports that provides cartilage degeneration market statistics, including cartilage degeneration industry global market size, regional shares, competitors with a cartilage degeneration market share, detailed cartilage degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the cartilage degeneration industry. This cartilage degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the cartilage degeneration market report are Johnson & Johnson Services Inc., MEDIPOST Co. Ltd., Medtronic PLC, Stryker Corporation, Zimmer Biomet Holdings Inc., Smith and Nephew PLC, B Braun Melsungen AG, Osiris Therapeutics Inc., Arthrex Inc., Conmed Corporation, Orthocell Ltd., Bioventus LLC, Aesculap Inc., Vericel Corporation, Anika Therapeutics Inc., Geistlich Pharma AG, MatTek Corporation, Breg Inc., Isto Biologics Inc., OrthoTrophix LLC, CellGenix GmbH, CartiHeal Inc., Cayenne Medical Inc., Collagen Solutions PLC, Regentis Biomaterials Ltd., Histogen Inc., BioTime Inc., CollPlant Holdings Ltd.

North America was the largest region in the cartilage degeneration market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cartilage degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cartilage degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The cartilage degeneration market consists of revenues earned by entities by provide services such as diagnosis and evaluation, non-surgical management, patient education, physical therapy, and nutritional and lifestyle guidance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cartilage degeneration market also includes sales of over-the-counter medications, joint supplements, topical pain relievers, and hyaluronic acid injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.